Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in Fourth ... MarketWatch (press release) Presented New Daclizumab Data at Multiple Sclerosis Congress Announced with our partner company Biogen Idec additional results from the SELECT Phase 2b trial, the first of two registrational studies designed to evaluate daclizumab high-yield process ... |
